statistiche ricercatore

Continente	#
NA - Nord America	1.444
AS - Asia	550
EU - Europa	517
SA - Sud America	68
AF - Africa	14
Continente sconosciuto - Info sul continente non disponibili	2
Totale	2.595

Nazione	#
US - Stati Uniti d'America	1.434
SG - Singapore	232
GB - Regno Unito	167
CN - Cina	110
DE - Germania	81
IT - Italia	77
BR - Brasile	55
VN - Vietnam	53
SE - Svezia	46
HK - Hong Kong	45
IN - India	30
FI - Finlandia	25
FR - Francia	25
TR - Turchia	23
RU - Federazione Russa	22
UA - Ucraina	20
BE - Belgio	13
AE - Emirati Arabi Uniti	9
BG - Bulgaria	9
NL - Olanda	8
AR - Argentina	7
KR - Corea	7
IQ - Iraq	6
PH - Filippine	6
BD - Bangladesh	5
ID - Indonesia	5
ZA - Sudafrica	5
ES - Italia	4
JP - Giappone	4
MX - Messico	4
AT - Austria	3
CA - Canada	3
MA - Marocco	3
PK - Pakistan	3
PL - Polonia	3
UZ - Uzbekistan	3
AO - Angola	2
CH - Svizzera	2
CL - Cile	2
CO - Colombia	2
CZ - Repubblica Ceca	2
DZ - Algeria	2
EC - Ecuador	2
HU - Ungheria	2
JO - Giordania	2
SA - Arabia Saudita	2
SI - Slovenia	2
XK - ???statistics.table.value.countryCode.XK???	2
AL - Albania	1
AZ - Azerbaigian	1
BS - Bahamas	1
CR - Costa Rica	1
EG - Egitto	1
IE - Irlanda	1
IR - Iran	1
LT - Lituania	1
NO - Norvegia	1
NP - Nepal	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
TN - Tunisia	1
Totale	2.595

Nome	#
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel	382
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort	376
Modeling cost-effectiveness and health gains of a âuniversalâ versus âprioritizedâ hepatitis C virus treatment policy in a real-life cohort	319
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study	311
Missed treatment in an Italian HBV infected patients cohort: HBV RER	287
From current status to optimization of HCV treatment: Recommendations from an expert panel	272
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis	232
CFD analysis of compensator for meter out sensing system	220
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group	217
Totale	2.616

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	59	0	0	0	0	0	0	0	0	0	22	26	11
2021/2022	209	16	10	9	18	3	9	15	19	18	21	42	29
2022/2023	221	26	32	24	29	27	29	2	14	22	0	11	5
2023/2024	111	6	8	12	11	11	12	11	11	2	4	3	20
2024/2025	422	19	0	6	31	79	59	17	37	62	14	43	55
2025/2026	652	54	18	38	72	171	56	82	33	70	58	0	0
Totale													2.616